A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN PATIENTS WITH RESECTED EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER IN PORTUGAL

被引：0
|
作者：
Andrade, A. [1 ]
Tavares, A. L. [1 ]
机构：
[1] Astrazeneca, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE72
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [1] Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
    Verhoek, Andre
    Cheema, Parneet
    Melosky, Barbara
    Samson, Benoit
    Shepherd, Frances A.
    de Marinis, Filippo
    John, Thomas
    Wu, Yi-Long
    Heeg, Bart
    Van Dalfsen, Nadia
    Bracke, Benjamin
    Miranda, Miguel
    Shaw, Simon
    Moldaver, Daniel
    [J]. PHARMACOECONOMICS-OPEN, 2023, 7 (03) : 455 - 467
  • [2] Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
    Andre Verhoek
    Parneet Cheema
    Barbara Melosky
    Benoit Samson
    Frances A. Shepherd
    Filippo de Marinis
    Thomas John
    Yi-Long Wu
    Bart Heeg
    Nadia Van Dalfsen
    Benjamin Bracke
    Miguel Miranda
    Simon Shaw
    Daniel Moldaver
    [J]. PharmacoEconomics - Open, 2023, 7 : 455 - 467
  • [3] COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
    Holleman, M. S.
    Al, M. J.
    Uyl-de Groot, C. A.
    [J]. VALUE IN HEALTH, 2018, 21 : S3 - S3
  • [4] Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
    Lemmon, Christopher A.
    Zabor, Emily C.
    Pennell, Nathan A.
    [J]. ONCOLOGIST, 2022, 27 (05): : 407 - 413
  • [5] Osimertinib for treating Patients with EGFR Mutation-Positive non-small cell Lung Cancer
    Meinrenken, Susanne
    [J]. PNEUMOLOGIE, 2018, 72 (04): : 246 - 246
  • [6] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
    Alsharedi, M.
    Bukamur, H.
    Elhamdani, A.
    [J]. DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
  • [7] Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.
    Lemmon, Christopher
    Zabor, Emily Craig
    Pennell, Nathan A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
    Cai, Hongfu
    Zhang, Longfeng
    Li, Na
    Chen, Shen
    Zheng, Bin
    Yang, Jing
    Weng, Lizhu
    Liu, Mao-Bai
    [J]. CLINICAL THERAPEUTICS, 2019, 41 (02) : 280 - 290
  • [9] Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy
    Wu, Bin
    Gu, Xiaohua
    Zhang, Qiang
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 184 - 193
  • [10] OSIMERTINIB AS FIRST-LINE AND SECOND-LINE THERAPY FOR EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN CHINA
    Zhou, J.
    Jiang, G.
    [J]. VALUE IN HEALTH, 2020, 23 : S54 - S54
12345